Denver, CO – April 30, 2025 – HepQuant, LLC announces that Dr. Greg T Everson, CEO and founder, will present “Simultaneous Quantification of Native Human Liver and Porcine Liver Function... read more →
Recent clinical data demonstrates how HepQuant DuO test results may be used to inform endoscopy screening decisions, monitor disease progression and evaluate response to resmetirom therapy in patients with... read more →
Kelly R. Pitts, PhD, Chief Operating Officer; Carrie Mulherin, MBA, Chief Commercial Officer; Shailesh Chavan, MD, Chief Medical Officer; Paige Nardi, MBA VP Market Access Denver, CO – June 13,... read more →
Medical Diagnostics Industry Veteran with Biotech and Biopharma Experience Will Guide Operations DENVER (Apr. 14, 2023) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for... read more →
The HepQuant Lab has moved a short distance within the Fitzsimons Innovation Community Campus to Bioscience 1, located at 12635 E. Montview Blvd., Suite 175, Aurora, CO 80045. The... read more →
DENVER (Aug. 24, 2022) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that the HepQuant... read more →